Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients.

Q3 Medicine Advances in Hematology Pub Date : 2020-05-20 eCollection Date: 2020-01-01 DOI:10.1155/2020/9545717
Salah Aref, Mohamed El Agdar, Nada Khaled, Lamyaa Ibrahim, Mohamed S El-Ghonemy
{"title":"Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients.","authors":"Salah Aref,&nbsp;Mohamed El Agdar,&nbsp;Nada Khaled,&nbsp;Lamyaa Ibrahim,&nbsp;Mohamed S El-Ghonemy","doi":"10.1155/2020/9545717","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to determine the clinical impact of CD25<sup>+</sup>/CD123<sup>+</sup> coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25<sup>+</sup>/CD123<sup>+</sup> coexpression was detected in 40/120 B-ALL patients (33.3%). All B-ALL patients showed CD25<sup>+</sup>/CD123<sup>+</sup> coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25<sup>+</sup>/CD123<sup>+</sup> positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2020 ","pages":"9545717"},"PeriodicalIF":0.0000,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9545717","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/9545717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to determine the clinical impact of CD25+/CD123+ coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25+/CD123+ coexpression was detected in 40/120 B-ALL patients (33.3%). All B-ALL patients showed CD25+/CD123+ coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25+/CD123+ positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人b细胞急性淋巴细胞白血病患者CD25/CD123共表达的临床影响
本研究旨在确定CD25+/CD123+共表达在成人b细胞急性淋巴细胞白血病(B-ALL)病例中的临床影响。本研究纳入120例新诊断的B-ALL患者(年龄≤60岁)。流式细胞术检测CD123和CD25在白血病母细胞中的表达。在40/120 B-ALL患者中检测到CD25+/CD123+共表达(33.3%)。与缺乏共表达的B-ALL患者相比,所有显示CD25+/CD123+共表达的B-ALL患者的缓解反应诱导较低,总生存期较短。综上所述,CD25+/CD123+阳性共表达是预测成人B-ALL患者预后的可靠的流式细胞术标志物,可作为成人B-ALL患者风险分层的新参数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in Hematology
Advances in Hematology Medicine-Hematology
CiteScore
3.30
自引率
0.00%
发文量
10
审稿时长
15 weeks
期刊最新文献
Variability in Notification of Positive Newborn Screening Results for Sickle Cell Trait Across the United States. Early Molecular Response to Imatinib First-Line Therapy and Predictive Factors of Poor Outcomes for Chronic Myeloid Leukemia Patients in Côte d'Ivoire. Relationships Between Markers of Iron Status and Hematological Parameters in Patients With Sickle Cell Disease. A Comparative Analysis of Hydroxyurea Treatment on Coagulation Profile Among Sickle Cell Anaemia Children in Lagos, Nigeria. Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1